Merck 0.36% Drop and 86th-Ranked Liquidity as FDA Delays and Partnership Doubts Weigh

On October 3, 2025, Merck (MRK) closed with a 0.36% decline, trading on $1.16 billion in volume that ranked it 86th in market liquidity. The stock’s performance reflected mixed signals from regulatory and partnership developments in its key therapeutic areas.

A critical update emerged regarding the FDA’s review timeline for Merck’s experimental oncology drug, which now faces a potential delay of several months due to additional data requests. Analysts noted the postponement could impact investor sentiment ahead of anticipated clinical trial milestones in late 2025.

Merck’s partnership with a European biotech firm for a novel antiviral candidate also drew attention. While the collaboration expands its R&D pipeline, uncertainty around Phase II trial enrollment rates has tempered immediate market optimism. The stock’s liquidity profile remains robust, but recent volatility suggests sensitivity to near-term execution risks.

For the back-test strategy outlined, the system would: (1) rank all stocks daily by dollar volume; (2) purchase the top 500 names at the next open/close; (3) hold positions for one day before exiting and repeating. Current tools support single-asset analysis or event-driven strategies but lack portfolio rebalancing capabilities across multiple names. A proxy approach using liquid ETFs or external platforms like Python/Zipline is recommended for full implementation.